| Business Summary | | Repligen
Corporation
develops
new
drugs
for
autism,
immune
system
diseases
and
mitochondrial
disease.
The
Company's
lead
therapeutic
products
are
secretin
for
autism,
CTLA4-Ig
for
stem
cell
transplantation
and
uridine
for
mitochondrial
disease.
The
Company
also
manufactures
and
markets
products
based
on
Protein
A
for
the
purification
of
antibodies,
and
it
owns
commercial
rights
to
two
products
based
on
synthetic
forms
of
secretin
for
the
diagnosis
of
pancreatic
function. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Repligen
develops
new
drugs
based
on
naturally
occurring
peptides
and
proteins
for
autism,
organ
transplantation
and
immune
system
diseases.
For
the
three
months
ended
6/30/01,
revenues
increased
8%
to
$713
thousand.
Net
loss
increased
38%
to
$1.3
million.
Revenues
reflect
a
large-scale
production
order
of
Protein
A.
Higher
loss
suffered
from
increased
costs
associated
with
drug
development
programs. | More
from
Market Guide: Significant
Developments |
| | | | FY2001 Pay | |
| Alexander Rich, M.D., 76 Co-Chairman | -- | Paul Schimmel, Ph.D., 60 Co-Chairman | -- | Walter Herlihy, Ph.D., 49 Pres,
CEO, Treasurer, Director | $260K | James Rusche, Ph.D., 47 VP-
R&D | 175K | Daniel Witt, Ph.D., 53 VP-Bus.
Devel., Sec. | 152K | Dollar amounts are as of 31-Mar-2001 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|